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The sequential enzymatic actions of-APP cleaving enzyme 1 (BACE1), presenilins (PS), and other proteins of the -secretase complex
liberate-amyloid (A) peptides from larger integralmembraneproteins, termed-amyloid precursor proteins (APPs). Relatively little
is known about the normal function(s) of APP or the neuronal compartment(s) in which APP undergoes proteolytic processing. Recent
studies have been interpreted as consistent with the idea that APP serves as a kinesin-1 cargo receptor and that PS and BACE1 are
associated with the APP-resident membranous cargos that undergo rapid axonal transport. In this report, derived from a collaboration
among several independent laboratories, we examined the potential associations of APP and kinesin-1 using glutathione S-transferase
pull-down and coimmunoprecipitation assays. In addition, we assessed the trafficking of membrane proteins in the sciatic nerves of
transgenicmice with heterozygous or homozygous deletions ofAPP. In contrast to previous reports, we were unable to find evidence for
direct interactions between APP and kinesin-1. Furthermore, the transport of kinesin-1 and tyrosine kinase receptors, previously re-
ported to require APP, was unchanged in axons of APP-deficient mice. Finally, we show that two components of the APP proteolytic
machinery, i.e., PS1 and BACE1, are not cotransported with APP in the sciatic nerves of mice. These findings suggest that the hypothesis
that APP serves as a kinesin-1 receptor and that the proteolytic processingmachinery responsible for generatingA is transported in the
same vesicular compartment in axons of peripheral nerves requires revision.
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Introduction
-amyloid (A) peptides, the principal components of paren-
chymal amyloid deposits inAlzheimer’s disease (AD), are derived
frommembrane glycoproteins known as amyloid precursor pro-
teins (APPs) (Price and Sisodia, 1998; Selkoe, 2001). A peptides
are liberated from APP by the sequential activities of a -APP
cleaving enzyme 1 (BACE1) aspartyl protease and a proteolytic
complex, termed “-secretase” (for review see, Selkoe, 2001) con-
sisting of presenilin (PS), nicastrin, PEN-2 (presenilin enhancer),
and APH-1 (anterior pharynx defective) (De Strooper, 2003).
APP is transported in the fast component of anterograde
transport in both peripheral and central axons (Koo et al., 1990;
Sisodia et al., 1993; Buxbaum et al., 1998; Kaether et al., 2000),
and membrane-tethered APP derivatives accumulate at terminal
fields in the CNS (Buxbaum et al., 1998). Several lines of evidence
indicate that A is released at nerve terminals in the CNS (Laz-
arov et al., 2002; Sheng et al., 2002), but the neuronal compart-
ments inwhich-secretase processing occurs have not been iden-
tified. The findings that APP interacts with the tandem repeat
(TR) domains of kinesin-1 light chain (KLC) and that antero-
grade transport of APP is impaired in the sciatic nerves of KLC1-
deficient mice, led to the hypothesis that APP is a kinesin-1 cargo
receptor (Kamal et al., 2000). More recently, it has been reported
that PS1 is rapidly transported in amembranous axonal organelle
that also contains BACE1 and APP (Kamal et al., 2001). A pep-
tides seemed to be present in sciatic nerves, and the accumulation
of these peptides at the proximal stump of ligated nerve led these
authors to suggest that the concerted action of BACE1 and PS–
secretase couldmediate proteolysis of APPwithin axonally trans-
ported vesicles during transit along peripheral nerves (Kamal et
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al., 2001). In view of the substantial implications of these propos-
als for understanding the functions of APP and the transport of
the secretases in both controls and cases of AD, we sought to
reexamine these issues.
This report brings together data from six laboratories that
examine the hypothesis that APP serves as a kinesin-1 cargo re-
ceptor and that the proteolytic machinery responsible for gener-
ating A from APP are cotransported within APP-containing
cargos. We show that recombinant fusion proteins containing
various regions of either KLC1 or the cytoplasmic domains of
APP can interact, but in a manner that is inconsistent with a
specific association. Moreover, endogenous APP did not cofrac-
tionate with kinesin-1 in membrane fractions or detergent ho-
mogenates prepared frommouse brain. Significantly, we demon-
strate that axonal transport of kinesin-1 and tyrosine kinase (Trk)
receptors are not altered in the absence of APP in APP/mice.
These studies do not support the hypothesis that APP is a
kinesin-1 cargo receptor. Finally, biochemical and immunocyto-
chemical assays show that neither PS1 nor BACE1 is cotrans-
ported with APP in sciatic nerves of mice. These observations,
coupled with our inability to detect BACE1 and A in sciatic
nerves, suggests that in the PNS it is unlikely that there exists a
coordinated axonal transport of the proteolytic processing ma-
chinery responsible for generating A peptides.
Materials andMethods
Cloning of green fluorescent protein and glutathione S-transferase fusion
proteins.Green fluorescent protein (GFP) fusion proteins were generated
by subcloning of the enhanced GFP (EGFP) cDNA (Invitrogen, Gaith-
ersburg,MD) in framewith the cDNA for humanAPP695 constructs into
pcDNA3.1. Constructs included APP intracellular domain (AID; amino
acids 649–695) and mutant AID missing the basolateral sorting signal
(AIDBaSS; amino acids 652–656), the PEER motif domain
(AIDPEER; amino acids 669–679), or the NPTY motif domain
(AIDNPTY; amino acids 680–691). KLC1 cDNA (a kind gift from Dr.
Lachman) and KLC1 deletionmutants were cloned in frame into pGEX-
4T-2 (Amersham Biosciences, Arlington Heights, IL) glutathione
S-transferase (GST-KLC). Deletion constructs included the following:
C-terminal deletions (amino acids 1–500, KLC-CC/TPR; amino acids
1–363, KLC-CT), the C terminus with all tandem repeats (amino acids
199–444; KLC-TR), the N terminus with the coiled coil domain (amino
acids 1–181; KLC-CC), and an N-terminal deletion (amino acids 362–
567; KLC-NT). GST-APP/amyloid precursor-like protein (APLP) fu-
sion proteins were generated by cloning the intracellular domain of APP
(AID; amino acids 649–695), APLP1 (ALID1; amino acids 604–650),
and APLP2 (ALID2; amino acids 717–763) in frame into pGEX4T-1
(Amersham Biosciences).
Expression and purification of GST fusion proteins in Escherichia coli.
Expression of GST and GST fusion proteins was performed in 200 ml of
BL21 E. coli cultures (DE3 strain; Novagen, Madison,WI) by addition of
1mM isopropyl--D-thiogalactopyranoside atOD0.3. After 2 h of induc-
tion, bacteria were lysed by incubating for 30minwith 1mg/ml lysozyme
plus 1 mM PMSF in PBS, pH 7.4, and sonicated with a Branson Sonifier
250 (24 times 30 pulses; Branson Ultrasonic, Danbury, CT). Triton
X-100 was added to a final concentration of 1%, and cell lysates were
centrifuged for 30 min at 20,000  g at 4°C. Supernatant containing
soluble GST or GST fusion proteins was incubated with 0.5 ml of
glutathione-Sepharose beads (Amersham Biosciences) for 1 h at room
temperature. Insoluble GST fusion proteins were solubilized in 6 ml of 6
M guanidinium HCl, 100 mM Tris, pH 8, and 50 mM DTT and sonicated
again (two times 20 s on ice). Solubilized GST fusion proteins were
incubated overnight at 4°C on a magnetic stirrer. Refolding of GST fu-
sion proteins was performed by pulse renaturation in 1 M arginine, 100
mM Tris, pH 8, 5 mM DTT, and 2 mM EDTA starting with 0.1 mg/ml
protein and a final concentration after the last pulse of 1.5 M guani-
diniumHCl. The refolded GST fusion proteins were dialyzed in PBS, pH
7.4, at 4°C and centrifuged at 40,000 g for 30min. The supernatant was
incubated with 1 ml 50% glutathione-Sepharose beads for 1 h at room
temperature. Loaded beads were washed three times with PBS, pH 7.4,
and stored at 4°C as a 50% slurry. Protein concentration was determined
using the Bio-Rad (Hercules, CA) protein assay.
Coupled in vitro transcription–translation. The in vitro transcription–
translation was performed using in vitro TNT 7 Quick Coupled Tran-
scription–Translation System (Promega, Madison, WI) with 1 g of
pCDNA3.1-GFP, -GFP-AID, -GFP-AIDBaSS, -GFP-AIDPEER, or
-GFP-AIDNPTY, GFP-ALID1, GFP-ALID2, Fe65, Numb, and PAT1a
DNA with 250 Ci of [ 35S]methionine for labeling according to the
manufacturer’s instructions.
GST binding assay. An aliquot (8 l) of in vitro-translated GFP or
GFP-AID fusion proteins was incubated with 20 l of glutathione-
Sepharose beads (Amersham Biosciences) coupled with GST or GST
fusion proteins for 1 h at room temperature in 750l of buffer H [50mM
Tris, pH 6.8, 50 mM KCl, 100 mM NaCl, 2 mM CaCl2, 2 mM MgCl2, 1%
(w/v) BSA, 0.1% (w/v) Triton X-100, 5 mM DTT]. Protein-bound beads
were washed three times in buffer H, and bound proteins were analyzed
by SDS-PAGE (12%Tris-glycine gels). Gels were subsequently dried and
exposed for autoradiography (MS films; Amersham Biosciences)
overnight.
Antibodies, immunoprecipitation, andWestern blot analyses. ForWest-
ern blot or immunoprecipitation–Western blot, the following antibodies
were used as described previously: anti-APP N-terminus monoclonal
antibody (mAb) 22C11 (Weidemann et al., 1989; Hilbich et al., 1993),
anti-APP C-terminal polyclonal serum [CT15 (Sisodia et al., 1993),
AB5352; Chemicon, Temecula, CA]; JF, a rabbit polyclonal serum pro-
vided by Joachim Herz (University of Texas Southwestern, Dallas, TX),
mouse anti--tubulin (Sigma, St. Louis, MO), anti--tubulin (TUB2.1;
Sigma), anti-PP2A (sc-6110; Santa Cruz Biotechnology, Santa Cruz,
CA), rabbit anti-JIP3/Sunday Driver (SYD) SN1 serum (a gift from L. S.
Goldstein, University of California San Diego, La Jolla, CA), anti-
synapsin I (MCA1224G; Serotec, Indianapolis, IN), rabbit anti-mouse
PS1-N-terminal fragments (PS1-NTF) (Thinakaran et al., 1997), anti-
kinesin light chain antibodies [63–90 (Stenoien and Brady, 1997)], L1,
L2, and KLC-ALL (Pfister et al., 1989), anti-kinesin heavy chain H2 and
SVK4 (Brady et al., 1990), anti-dynein (mAb 1618; Chemicon), anti-
synaptophysin (P38, SY38 clone; Boehringer Mannheim, Mannheim,
Germany), H-93 (Santa Cruz Biotechnology), anti-low-molecular-
weight neurofilament (anti-NFL) (Tu et al., 1995), anti-Trk (C14, s.c.-11;
Santa Cruz Biotechnology), and anti-BACE1 antibodies [gifts from Drs.
Seidah (Marcinkiewicz and Seidah, 2000), Xu (Shi et al., 2003), and
Wong (Cai et al., 2001)]. For A immunoprecipitation–Western blot,
26D6 mAb raised against aa 1-16 of A was used (Lamb et al., 1999). In
Figure 3A, full-length APP was detected in the sciatic nerve by immuno-
precipitation using rabbit anti-APP C-terminal 5685 antibody, followed
by Western blot analysis using goat anti-APP N-terminal Karen anti-
body (Lee et al., 2005). The following antibodies were used for immuno-
histochemistry: CT15, 6E10 mAb raised against aa 1-17 of human A,
and affinity-purified rabbit anti-mouse PS1-NTF (Kim et al., 2001). PS1-
NTF glutathione S-transferase fusion protein was used as a competition
peptide for antibody-specificity assay (Kim et al., 2000). Nerve extracts
were subject to Tris-glycine or Tris-tricine SDS-PAGE. Proteins were
detected as described previously (Kim et al., 2000). Immunoprecipita-
tion of A and APP fragments from nerve extracts was performed as
described previously (Kim et al., 2001). Briefly, protein extracts were
suspendedwith an equal volume of immunoprecipitation (IP) buffer (50
mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholic
acid, 0.5% NP-40) in the presence of a protease inhibitor mixture
(Sigma) and 100 mM PMSF. The samples were boiled for 3 min and
precleared with immobilized protein A-agarose (Pierce, Rockford, IL)
for 30 min at 4°C. Samples were then incubated with antibodies over-
night at 4°C. Complexes were collected using immobilized protein A- or
G-agarose and washed with IP buffer for 30 min. Complexes were then
loaded on 1 M sucrose gradient and centrifuged at 9000  g, and the
pellets were resuspended in sample buffer and boiled for 5 min before
running. Stably transfected N2a cells used as positive controls in these
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experiments have been described previously (Thinakaran et al., 1996).
Each one of the presented experiments was repeated at least three times.
Immunohistochemistry. Mouse sciatic nerves were frozen in dry ice–
cold isopropanol and embedded in Tissue-Tek optimal cutting temper-
ature compound (Sakura, Tokyo, Japan). Cryostat sections (10m)were
fixed with 3.7% paraformaldehyde solution for 30 min at room temper-
ature. Sections were washed and then blocked and permeabilized with
0.25% Triton X-100–5% donkey serum in Tris buffer solution for 2 h at
room temperature. Sections were incubated with primary antibodies for
2 h at room temperature, washed, and incubated with FITC or cyanine
3-conjugated secondary antibodies for 1 h. Sections were washed and
mounted with glycerol-based mounting medium (polyvinyl alcohol
mounting medium with antifading 1,4-diazabicyclo-[2.2.2]octane;
Sigma). For specificity verification, PS1-NTF antibodies were incu-
bated with PS1-NTF glutathione S-transferase fusion protein for 2 h at
4°C before their introduction to cryostat sections. Images were taken
using an Olympus (Melville, NY) Fluoview confocal laser scanning mi-
croscope equipped with Fluoview 2.1 software.
Transgenic mice. The background of wild-type nontransgenic mice is
[C3H/HeJ C57BL/6J F3] C57BL/6J n1. Mice expressing a chimeric
mouse–human APP695 harboring a human A domain and mutations
(K595N, M596L) linked to Swedish familial Alzheimer’s disease (FAD)
pedigrees (APPswe) have been described previously (Borchelt et al.,
1996, 1997; Lee et al., 1997). The background strains for APPswe are
[C3H/HeJ  C57BL/6J F3]  C57BL/6J n1. Tg2576 mice have been
described previously (Hsiao et al., 1996). BACE1-deficient mice have
been described previously (Cai et al., 2001). APP-deficient (KO) mice
(Zheng et al., 1995) were obtained from Dr. Hui Zheng (Baylor Medical
School, Houston, TX). Mice used in this study were 5 months of age.
Sciatic nerve ligation. Mice were anesthetized using a mixture of ket-
amine (75mg/kg) and xylazine (4mg/kg). The skin on the lateral surface
of the right thighwas incised, and a sectionwasmade directly through the
biceps femoris muscle. The sciatic nerve was exposed and doubly ligated
using 4-0 silk sutures (Ethicon, New Brunswick, NJ). The skin was
clippedwith wound clips. Six or 24 h later, nerve segments (up to 0.5 cm)
proximal and distal to the ligature were collected and frozen on dry ice.
The contralateral nerve was kept intact. Corresponding contralateral
nerve and cortex tissue were collected as well.
Sciatic nerve-crush injury.Mice were deeply anesthetized using isoflu-
orane, and the left sciatic nerve was exposed and crushed for 20 s by
pressing the nerve between Dumont blunt-tipped jeweler’s forceps. The
crush site was2 cm distal to the L4/L5 articulation.Muscle was sutured
using 5-0 polysorb suture (Ethicon), and the skin was clipped. Twenty-
four hours later, sciatic nerve segments proximal and distal to the crush,
as well as intact contralateral sciatic nerve segments, were dissected and
frozen on dry ice.
Protein extraction from nerve. Sciatic nerve segments were homoge-
nized in extraction buffer [50 mM Tris, pH 7.2, 150 mM NaCl, 5 mM
EDTA, protease inhibitor mixture (Sigma), and 100 mM PMSF] using a
glass-made microhomogenizer. After the addition of 1% SDS, the ho-
mogenate was centrifuged for 10 min. The protein concentration of the
supernatant was determined using BCA protein assay (Pierce), and ex-
tract samples of equal amounts of proteinswere analyzed byWestern blot
(see above).
Vesicle fractionation. Vesicle fractions were performed as described
previously (Morfini et al., 2001, 2002) using adult mouse brains. Brains
were homogenized in 10 ml of buffer [300 mM sucrose, 10 mM HEPES,
pH 7.4, 5 mM EDTA, and 2% mammalian protease inhibitor mixture
(Sigma)] and then centrifuged at 12,500 gmax to eliminate cell debris,
nuclei, and most mitochondria. Pellets from subsequent centrifugation
steps generated three vesicle fractions: V0 (39,800 gmax), V1 (120,000
gmax), and V2 (260,000 gmax). The final supernatant was termed cytosol.
For immunoblots, equal amounts of protein from V0, V1, V2, and cy-
tosol fractions were used.
Immunoprecipitation of APP and kinesin-1 from mouse brain. Immu-
noprecipitations were performed as described by Kamal et al. (2000) and
Rahman et al. (1999). Mouse brain was homogenized in 3 ml of NP-40
homogenization buffer (NB; 1% NP-40, 150 mM NaCl, 50 mM Tris, pH
8.0). Brain lysate was spun at 35,000 rpm for 10 min (TLA100.3 rotor;
66,000  gmax; Beckman Coulter, Fullerton, CA), and the supernatant
was collected. Protein A-Sepharose beads (Bio-Rad) were preblocked
with 5% bovine serum albumin in NB for 1 h at 4°C and washed with NB
before use. One hundredmicroliters of brain extract were brought to 800
l with NB and precleared by incubating with 20 l of protein
A-Sepharose beads (Bio-Rad) for 1 h at 4°C. The solution was spun at
3000 rpm for 2 min in a microcentrifuge, and the supernatant was col-
lected. The precleared brain lysate was then incubated with 5 g each of
affinity-purified monoclonal antibodies [SUK4, H2, 63–90, L1, L2,
22C11, normal mouse or rabbit IgG (Jackson ImmunoResearch, West
Grove, PA)] or 5l of polyclonal anti-APPC terminus (AB5352; Chemi-
con) or antibodies directed against the last 13 residues of APP (JH; a
generous gift from J. Herz, University of Texas Southwestern Medical
Center, Dallas, TX). Lysates were incubated with rotation for 2 h at 4°C
before adding 20 l of protein A-Sepharose for an additional 1 h at 4°C.
The solution was centrifuged as above, and the pellet and supernatant
aliquots were saved. The pellet was washed three times in 1ml of NB and
finally washed one time in 500 l of 50 mM Tris, pH 6.8. Equivalent
amounts of immunoprecipitate were loaded on a 4–16%SDS-PAGE and
processed for Western blotting as described above.
Results
APP does not bind directly to kinesin-1
Previous studies reported that the cytoplasmic domain of APP
exhibits high affinity (16–18 nM) with KLC1 and KLC2 and
that this interaction occurs with the KLC TR domains (Kamal et
al., 2000). These data, together with the demonstration of the
recovery of APP using antibodies raised against kinesin-1 heavy
chain (KHC) or KLC and a reduction in levels of steady state or
axonally transported APP in nerves from KLC1-deficient mice,
led to the proposal that APP may serve as a kinesin-1 cargo re-
ceptor (Kamal et al., 2000).
To examine the hypothesis that APP interacts directly with
kinesin-1, we performed three series of experiments. First, to
evaluate the interactions between AID and KLC1, as well as to
map potential interaction sites, various recombinant KLC1 and
APP fusion proteins were used for in vitro binding assays (Fig. 1).
Bacterially expressed GST-KLC constructs (Fig. 1A) were immo-
bilized on glutathione-Sepharose beads and incubated with in
vitro-translated, [35S]methionine-labeled GFP and GFP-AID fu-
sion proteins (Fig. 1B). As described previously (Kamal et al.,
2000), GST-KLC constructs containing the full set of TRs (GST-
KLC-CC/TR) pulled down GFP-AID. Surprisingly, GST-KLC
constructs containing only a subset of these repeats (GST-KLC-
TR) pulled down similar levels of GFP-AID (Fig. 1B). GST fusion
proteins carrying the entire TR domain bound with similar
strength as observed for GFP-AID to GFP fused to the intracel-
lular domain of APLP1 (GFP-ALID1) or APLP2 (GFP-ALID2)
(Fig. 1C), indicating that the differences in the primary sequence
of AID, ALID1, and ALID2 have no influence on the binding to
KLC. Furthermore, all of these constructs also pulled down the
highly soluble protein GFP, whereas GST and GST fused to a
mutant KLC1 lacking the TRs (GST-KLC-CC) failed to do so.
This observation suggested that the binding to GFP-AID was
unique toTR-containing constructs but raised the possibility that
this was caused by a nonspecific hydrophobic interaction. Con-
sistent with this, binding of GFP to GST-KLC was elevated in the
presence of high salt (500 mMNaCl) and reduced by higher con-
centrations of detergent (data not shown). Similarly, immobi-
lized GST-KLC also pulled down recombinant Fe65 (Fig. 1F), a
protein that is known to bind to AID (Kesavapany et al., 2002)
but was not expected to interact directly with KLC1. Similarly,
GST-KLC also pulled down PAT1a, a variant of PAT1 and mu-
tant PAT1a missing either the N-terminal or C-terminal half
(S.K., personal communication). These data indicate that GST-
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KLC1 constructs containing TRs interact with proteins as differ-
ent as GFP, Fe65, and PAT1a and the APP, APLP1, and APLP2
intracellular domains. Thus, the TR domains in GST-KLC1 ex-
hibit nonspecific binding to various polypeptides with suitable
hydrophobic patches. This might be explained by misfolding of
KLC1 in E. coli; therefore, we used GST-AID in a second set of
GST pull-down analyses and tested for binding of in vitro-
translated KLC1 (Fig. 1G) or recombinant KLC1 expressed in
COS-7 cells (data not shown). Neither the in vitro-translated
KLC1 nor the heterologously expressed KLC1 bound to GST or
GST-AID, whereas other known interaction partners of APP,
such as Fe65 or Numb, were specifically retained on beads loaded
with GST-AID (Fig. 1G). Together, these data show that bacteri-
ally expressed KLC1 has nonspecific binding properties and that
heterologously expressed or in vitro-translated KLC1, which has
fewer nonspecific binding characteristics, does not bind to the
APP intracellular domain.
Next, we prepared vesicle fractions from mouse brain under
conditions that preserve kinesin-1 association with membranes
(Tsai et al., 2000; Morfini et al., 2002) and examined the distri-
bution of KHC, KLC, and APP in these fractions byWestern blot
analysis. We detected KHC and KLC in all vesicle fractions (Fig.
2A, lanes V0, V1, V2) and in the cytosol (Fig. 2A, lane Cyt). Each
fraction had a characteristic stoichiometry and kinesin-1 (KLC
and KHC) isoform composition. In contrast, APP, detected with
an N-terminal antibody that detects both full-length and -
and/or -secretase-generated soluble ectodomain derivatives, is
associated primarily with V0 and V1 fractions with only trace
amounts in V2 and low levels in the cytosol. V2 did contain high
levels of KHC, KLC1, and KLC2, and the
membrane-associated proteins synapto-
physin (P38) and synapsin I. Some pro-
teins such as the catalytic subunit of pro-
tein phosphatase 2A and PKB (data not
shown) were enriched in the cytosolic
fraction. This suggests that kinesin-1 and
APP do not fully cofractionate in rodent
brain, as would be expected if APP acted as
the only cargo receptor for kinesin-1.
We then asked whether APP could be
immunoisolated with antibodies directed
against KHC or KLC. Immunoprecipita-
tion of kinesin-1 from mouse brain with
H2 antibodies, raised against KHC, show
that Coomassie blue (CB)-stained levels of
KHC were obtained, but no polypeptide
with a molecular weight corresponding to
APP was visible (Fig. 2B). Because immu-
noblots of whole-brain lysates readily re-
solved kinesin-1 heavy chain (H2) and
APP (22C11) in this gel system (Fig. 2B),
this could not result from either overlapping
bands or detection sensitivity. Furthermore,
APP and KHC were distinguishable even
when amixture of both antibodies (H2 plus
22C11) was used for immunoblotting. To
determine whether this was unique to spe-
cific antibodies,weusedabatteryofantibod-
ies raised against distinct epitopes on KHC
(Fig. 2C, lanes SUK4 and H2) or KLC (Fig.
2C, lanes 63–90 to KLC-ALL). We prepared
detergent-solubilized membranes from
mouse brain and performed immunopre-
cipitations as described by Kamal et al. (2000). APP could not be
coimmunoprecipitated at detectable levels with any of these anti-
bodies (Fig. 2C, lanes SUK4 to KLC-ALL). Similarly, KHC or KLC
could not be coimmunoprecipitated using three antibodies raised
against APP (Fig. 2C, lanes 22C11 to JH). Notably, the 22C11 anti-
bodydidnot recoverdetectable amountsofAPP in immunoprecipi-
tation, because the epitopebetweenaminoacids 66and81 ismasked
under the nondenaturing conditions used herein [(Hilbich et al.,
1993); S.S.S., datanot shown];however, twoantibodies to theAPPC
terminus (Ct-APP and JH) efficiently precipitated APP.
To enhance the ability to detect low-level interactions of APP
with kinesin-1, we performed multiple rounds of immunopre-
cipitation to deplete the target proteins. In this case, depletion of
the bulk of KHC from the lysate and corresponding supernatant
samples (Fig. 2E, KHC panel, lanes 1–4) results in a parallel
depletion in levels of KLC (Fig. 2E, KLC panel, lanes 1–4), but no
apparent change in levels of APP in either pellet or supernatant
fractions (Fig. 2E, Ct-APP panel, lanes 1–4 and 13–16, respec-
tively). Similarly, APP could be significantly depleted from brain
lysates in multiple cycles with an APP C-terminal antibody (Fig.
2E, Ct-APP panel, lanes 9–12); however, no changes in either
KHC (Fig. 2E, KHC panel, lanes 9–12) or KLC (Fig. 2E, KLC
panel, lanes 9–12) levels were detectable after four cycles of APP
immunodepletion. No KHCwas detectable in any of the IPs with
AB5352, although themethods should detect as little as 1% of the
original kinesin-1 (see below). No evidence for a direct interac-
tion of kinesin-1 with APP was found in these immunohisto-
chemical studies.
To evaluate whether our buffer conditions maintain the asso-
Figure 1. Nonspecific binding of AID and GST-KLC1 fusion proteins containing TRs. A, Schematic representation of GST-KLC1
deletionmutants used inGSTpull-downassays. For details, seeMaterials andMethods.B, Pull-downassays show that all GST-KLC
constructs containing two or more TRs bind to in vitro-translated GFP-AID constructs and with lower affinity to the GFP-only
control. Neither GST alone nor GST-KLC-CC (both lacking TRs) pulled down GFP-AID or GFP. The fact that TR-containing constructs
pulled down both GFP-AID and to a lower extent the highly soluble protein GFP suggests that these are nonspecific protein–
protein interactions. C, In addition to GFP-AID, both GFP-ALID1 and GFP-ALID2 were retained to a very similar extent on GST-
KLCCT. Identical resultswereobtainedwithGST-KLC-TRorGST-KLC-CC/TRbeads (datanot shown).D, Schematic representation
of GFP-APP intracellular domain deletion mutants used in GST pull downs (see Materials and Methods). E, GST-KLC-CC/TR binds
with similar affinities to GFP-AID and GFP-AID constructs with deletions of the BaSS (G-AIDB), PEER (G-AIDP), or NPTY
(G-AIDN) domains of APP. These represent domains that have been shownpreviously to affect trafficking of APP andmap to the
domain proposed by Kamal et al. (2000) to bind TR domain in KLC1. F, Beads containing GST-KLCwith TR domains also pull down
recombinant Fe65with high affinity, again suggesting nonspecific binding of TR domains to proteins in this assay system.G, GST
pull downs with GST fused to the intracellular domain of APP demonstrated binding to the known APP interacting proteins Fe65
and Numb, whereas no binding of KLC1 was observed under identical conditions.
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ciation of kinesin-1 and a known kinesin-
1-associated protein, we asked whether
JIP3/SYD, a scaffolding protein for the
c-Jun N-terminal kinase (JNK) group of
kinases (Bowman et al., 2000) would co-
precipitate with kinesin-1 in our experi-
ments (Fig. 2D). We used buffer condi-
tions similar to those used by Kamal et al.
(2000, 2001) to reveal the association of
APP and kinesin-1. Significantly, anti-
kinesin-1 H2 antibodies coprecipitated
detectable levels of the scaffolding protein
JIP3/SYD (Fig. 2D, lane H2 IPP), and this
interaction was further confirmed by co-
precipitation of kinesin-1 using anti-JIP3
antibodies (Fig. 2D, lane SYD IPP). Semi-
quantitative analysis (data not shown) in-
dicates that 1% of total JIP3 from brain
lysate cofractionates with kinesin-1 (Fig.
2D, input lanes), in agreement with the
previous report [see Materials and Meth-
ods in Bowman et al. (2000)]. In summary,
no interaction between APP and kinesin-1
was detected in mouse brain membranes
under conditions that efficiently coisolate
KHC, KLC, and JIP3/SYD.
Axonal transport of kinesin-1 and Trk
receptors is independent of
APP expression
To confirm findings reporting decreased
steady-state levels and axonal transport of
KLC and selected cargo molecules in the
sciatic nerve of APP knock-out (KO) mice
(Kamal et al., 2001), we assessed the levels
of kinesin-1 in protein extracts prepared
from the sciatic nerves of mice with ho-
mozygous (Fig. 3A, Hm APP KO, lanes 1,
2) or heterozygous (Fig. 3A, Ht APP KO,
lanes 3, 4) deletions of APP and compared
the levels with kinesin-1 in nerves of wild-
type mice (Fig. 3A, APP WT, lanes 5, 6).
We found no change in the steady-state
levels of dynein and synaptophysin in
nerve segments for any of the different ge-
notypes (Fig. 3A, Dynein and Syp panels,
respectively). Specifically, we did not find
a reduction in the steady-state levels of
kinesin-1 heavy chains in nerves of APP-
deficient mice compared with nerves from
APP WT animals (Fig. 3A, KHC panel,
compare lanes 1–4, 5 and 6). We then
asked whether axonal transport of KHC,
KLC, TrkA, and PS1 were dependent on
APP expression, as reported previously
(Kamal et al., 2000, 2001). For this pur-
pose, we ligated sciatic nerves from wild-
type mice (Fig. 3B, lanes 7–9) and mice with heterozygous (Fig.
3B, lanes 4–6) or homozygous (Fig. 3B, lanes 1–3) deletion of
APP. Axonally transported material was allowed to accumulate
for 24 h, and Western blot analysis was performed on detergent
homogenates prepared from0.3 cm segments proximal or dis-
tal to the ligature. The levels of both KHC and KLC in proximal
segments from ligated nerves were essentially the same for nerves
from animals of the three different genotypes (Fig. 3B, KHC and
KLC panels, compare lanes 2, 5, 8). We also observed no differ-
ence in levels of Trk receptors (Fig. 3B, Trk panel, lanes 2, 5, 8)
that accumulate in the proximal segment of ligated nerves from
these animals. Because accumulation of kinesin-1 at the proximal
Figure 2. Kinesin-1 and APP do not cofractionate or coimmunoprecipitate from brain lysate. A, Subcellular fractionation of
mouse brain was performed as described previously (Morfini et al., 2002) to generate three vesicle fractions (V0, V1, and V2) and
a cytosolic fraction (Cyt). Under the conditions of fractionation, KHCs and KLCs are found in all fractions, but KLCs exhibit differ-
ences in stoichiometry and isoform composition. In contrast, APP immunoreactivity is associated primarily with V0 and V1
fractions, with only trace amounts in V2 and low levels in the cytosol. V2 contains high levels of KHC, KLC1, KLC2, synaptophysin
(P38), and synapsin I. This suggests that kinesin-1 and APP do not cofractionate in mouse brain. B, Immunoprecipitates of
kinesin-1 from mouse brain show that Coomassie blue-stained levels of kinesin-1 heavy chain are obtained (CB), but no band
corresponding to APPwas seen. Immunoblots ofwhole-brain lysate show that kinesin-1 heavy chain (H2) is readily resolved from
APP (22C11) in this gel system. These are distinguishable even when a mixture of both antibodies (H222C11) is used for
immunoblotting. C, Immunoprecipitation of kinesin-1 from mouse brain using antibodies against either kinesin-1 heavy chains
(SUK4 or H2) or light chains (63–90, L1, L2, or KLC-All) precipitated both KHC and KLC subunits (Pfister et al., 1989; Stenoien and
Brady, 1997). Nevertheless, APP could not be detected in immunoprecipitates using kinesin-1 antibodies. Brain lysate (L) was a
positive control. Negative controls, i.e., protein G beads without primary antibodies (B) or with normal mouse IgG show immu-
noprecipitation specificity. Similarly, kinesin-1 subunits were not detectable in immunoprecipitates with APP antibodies [Ct-APP
and JH; see KHC (H2) for kinesin-1 heavy chain, KLC (63–90) for kinesin-1 light chain]. Antigens in immunoprecipitates were
visualized using specific antibodies against kinesin-1 subunits (H2 or 63–90) or APP (22C11 or Ct-APP). D, Immunoblot analysis
showed detectable amounts of the scaffolding protein JIP3/SYD in kinesin-1 immunoprecipitates (H2 IPP). Conversely, anti-JIP3
antibodies (SYd IPP) coprecipitate small but detectable amounts of KHC. Immunoprecipitations with normal mouse (NM IPP) or
normal rabbit (NR IPP) IgGs were used as negative controls. Note the relative levels of JIP3/SYD compared with original protein
input. E, Immunodepletion of kinesin-1 andAPP frommouse brain lysate exhibits different depletion patterns. Immunodepletion
of KHC from lysate with H2 comparing IPs and corresponding supernatant samples shows a gradual reduction in the level of both
KHC (H2) and KLC (63–90) in the pellet (lanes 1–4) and the supernatant (lanes 13–16) after depletion cycles. In contrast, no
change in APP level could be detected (Ct-APP, lanes 1–4 and 13–16, respectively). Similarly, a reduction in APP level was
observed after depletion using APP-specific antibodies AB5352 (Ct-APP, pellet, lanes 9–12; supernatant, lanes 21–24), but no
change in the level of kinesin-1 could be detected (KHC, lanes 9–12, 21–24; KLC, lanes 9–12, 21–24).
2390 • J. Neurosci., March 2, 2005 • 25(9):2386–2395 Lazarov et al. • Axonal Transport, APPs, and Kinesin
side of the ligature, as detected byWestern blot, seemed to be less
robust than the accumulation of APP or Trk (Fig. 3B), we exam-
ined kinesin-1 expression in longitudinal sections of ligated sci-
atic nerve of wild-type mice (Fig. 3C). Consistent with previous
reports (Li et al., 1999), immunostaining using anti-KHC H2
antibodies confirmed accumulation ofKHC toward the proximal
stump of the ligature and reduced kinesin-1 expression distally
(Fig. 3C). Thus, we conclude that axonal transport of both
kinesin-1 and Trk occurs in an APP-independent manner. Our
lack of evidence for a direct association between kinesin-1 and
APP in brain and the absence of any effects of APP deficiency on
axonal transport of kinesin-1 and Trk suggest that APP does not
serve as a kinesin-1 cargo receptor.
Examination of PS1 expression in the samples in Figure 3B
revealed that steady-state levels of PS1 expression in unligated
nerves of mice were the same for all three genotypes (Fig. 3B,
PS1-NTF panel, compare lanes 1, 4, 7). In addition, we did not
observe an accumulation of PS1 at the segment proximal to the
ligature of sciatic nerves prepared from mice of any of these ge-
notypes (Fig. 3B, PS1-NTF panel, lanes 2, 5, 8). These findings
suggested that levels of PS1 in sciatic nerve were not APP depen-
dent and that the rapidly transported axonal vesicles that carry
APP are unlikely to transport PS1. These new findings led us to
investigate the proposal that PS1 is cotransported with APP in
fast axonal transport in the sciatic nerve.
Analysis of PS1 transport in mouse
sciatic nerve
Previous studies (Kamal et al., 2001; Papp
et al., 2002) reported that PS1 is subject to
rapid anterograde transport in mouse pe-
ripheral nerves. Moreover, Kamal et al.
(2001) proposed that PS1 is cotransported
with APP in the same vesicular compart-
ment, in which APP gets cleaved to yield
A peptides. In light of this, we examined
the axonal transport of PS1 and the pro-
duction of A peptides in nontransgenic
mice.We placed two ligatures in the sciatic
nerve just distal to the convergence of
L4/L5 sensory fibers and motor afferents
for 6 h and then prepared detergent-
solubilized extracts from 0.3 cm segments
proximal and distal to the ligatures. West-
ern blot analysis using the APP
C-terminal-specific antibody, CT-15, re-
vealed that only highly glycosylated forms
of full-length APP accumulate in the seg-
ment proximal to the ligature (Fig. 4A,
CT15 panel, lane 5; compare with unli-
gated contralateral nerve segment, lane 1,
and with other segments, lanes 2–4) over
this time frame, as described previously
(Koo et al., 1990; Sisodia et al., 1993). The
levels of underglycosylated APP remained
unchanged in all segments and are a reflec-
tion of the APP expressed by cells intrinsic
to the nerve, including Schwann cells and
fibroblasts. We showed previously that
these APP species are principally the APP-
751 variant (Sisodia et al., 1993). In con-
trast, using the PS1-specific PS1-NTF an-
tibody (Thinakaran et al., 1997), we were
unable to detect any increase in the levels
of theN-terminal, endoproteolytic derivative ofmouse PS1 (PS1-
NTF) in the proximal segment compared with the levels con-
tained in other isolated segments (Fig. 4A, PS1-NTF panel).
We considered the possibility that lack of PS1-NTF accumu-
lation in the proximal segment of ligated sciatic nerve, as
observed by Western blot analysis, may be a consequence of dis-
secting segments that were too wide, thus masking low levels of
PS1-NTF that might have accumulated immediately proximal to
the ligature. To examine this issue, we placed ligatures in the
sciatic nerve of nontransgenicmice and analyzed the distribution
of APP and PS1 in longitudinal, cryostat sections of the nerve by
immunolabeling and visualization by indirect immunofluores-
cence microscopy (Fig. 4B). Confirming theWestern blot analy-
sis (Fig. 4A), we obtained high levels of CT-15 immunoreactivity
in the segment proximal to the ligature andmarkedly lower levels
in the distal ligature in nerve sections of nontransgenicmice (Fig.
4B, panels A and B, respectively). Parallel analysis with an
affinity-purified preparation of the PS1-NTF antibody revealed
similar levels of accumulated PS1 in both proximal and distal
segments (Fig. 4B, panels C, D), with no apparent elevation in
PS1 immunoreactivity immediately proximal to the ligature.
PS1-NTF immunoreactivity in nerve segments was fully abol-
ished by preincubation of the antibody with the immunogen, a
GST fusion protein harboring the N-terminal 80 aa of PS1 (Fig.
4C, panel E). This data, and the demonstration that secondary
Figure 3. Expression and anterograde axonal transport of kinesin-1 and Trk receptor are APP independent. A, Protein extracts
of sciatic nerves fromwild-typemice (APPWT), micewith either homozygous or heterozygous APP depletion (HmAPP KO and Ht
APP KO, respectively), and transgenic mice harboring FAD-linked APPswe (Tg2576 mice). Immunoblots for KHC, dynein, synap-
tophysin (Syp), neurofilament (NF), and-tubulin show no differences at steady-state levels between the different genotypes,
indicating that fast, slow, anterograde, and retrograde axonal transport are not affected by APP expression. B, Protein extracts
prepared from ligated sciatic nerve of Ht APP KO, Hm APP KO, and APP WT mice. APP accumulation is evident in the proximal
ligature of sciatic nerve of APPWTmice (22C11panel, lane 8); reduced accumulation is observed in the proximal ligature of Ht APP
KOmouse sciatic nerve (22C11 panel, lane 5). APP expression cannot be detected in the sciatic nerve of APP KOmice (22C11 panel,
lanes 1–3). The accumulation level of Trk receptor (Trk panel), kinesin heavy chain (H2 antibodies, KHC panel), kinesin light chain
(63–90 antibodies, KLC panel), and PS1 (PS1-NTF antibodies, PS1-NTF panel) at the proximal stump of the ligation site is
comparable in sciatic nerve of APP-ablated and wild-type nontransgenic mice (compare lanes 2, 5, 8). I, Intact sciatic nerve; P,
proximal stump of ligated sciatic nerve; D, distal stump of ligated sciatic nerve. C, Kinesin-1 expression in longitudinal sections of
ligated sciatic nerve as detected by immunolabeling using anti-KHC H2 antibodies. Note kinesin-1 accumulation toward the
proximal stump of the ligature.
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antibodies alone (Fig. 4C, panel F) did not bind to nerve antigens,
led us to conclude that the immunofluorescence signal observed
using our PS1-NTF antibody is specific.
Together, these data indicate that APP and PS1 are not co-
transported in the nerve. Thus, the transport kinetics of these two
proteins is not consistent with the proposal that PS1 is antero-
gradely transported in a membrane compartment in which APP
serves as a kinesin-1 receptor (Kamal et al., 2001).
A and BACE1 are not cotransported with APP in the same
vesicular compartment
To examine the proposal that A peptides are generated within
axonally transported vesicles carried by the fast anterograde com-
ponent, we immunoprecipitated A from detergent extracts of
sciatic nerves of nontransgenic mice. A was not detected using
Western blot analysis or sandwich ELISA approaches (data not
shown). Because Kamal et al. (2001) reported that both A40 and
A42 peptides were readily detected in the transport component
in nerves of nontransgenic mice, we attempted to enhance detec-
tion of A in the sciatic nerve using antibody 26D6, raised against
amino acids 1–16 of A (Lamb et al., 1999), to immunoprecipi-
tate A from detergent extracts prepared from sciatic nerves of
APPswe mice. A was not detected in the proximal segment of
ligated nerve from the transgenic mice (Fig. 5A, lane 5), although
the 12 kDa APP C-terminal fragments (CTFs) were readily
evident and accumulated in this segment. APP CTFs were likely
to have been generated by -secretase processing of full-length
APPswe in the trans-Golgi network (Haass et al., 1995). To de-
termine whether our inability to detect A from nerve was a
reflection of one or more technical issues, we used N2a cells that
stably expressAPPswe and secrete abundant levels of A peptides
(Thinakaran et al., 1996). In addition, a segment of nerve in
immunoprecipitation buffer was added to conditioned medium
from homogenized APPsweN2a cells. This preparation was sub-
jected to immunoprecipitation and Western blot analysis with
26D6 antibody, as before (Fig. 5A). In parallel, an aliquot of the
conditioned medium from APPswe N2a cells, or detergent ho-
mogenate from the cortex of APPswe mice with an equivalent
amount of protein as the sciatic nerve extracts, was analyzed by
immunoprecipitation and Western blots. In cortices of APPswe
mice, we detected12 kDa APP-CTFs and very low levels of4
kDa A peptides (Fig. 5A, lane 3) (see long exposure). Identical
levels of soluble A peptides were immunoprecipitated fromme-
dium of APPswe cells and from the nerve homogenate that was
“spiked” with conditioned medium from APPswe N2a cells (Fig.
5A, lanes 1, 2). Thus, the absence of detectable levels of A pep-
tides in the proximal segment of nerve from APPswemice is not
caused by inhibitors present in the nerve preparation or other
technical limitations of the assay.
Finally, we examined the hypothesis that BACE1 is also trans-
ported in the same membranous compartment as APP. We per-
formed Western blot and immunoprecipitation analyses using
three independent antibodies (Marcinkiewicz and Seidah, 2000;
Cai et al., 2001; Shi et al., 2003). With our antibodies (Cai et al.,
2001), BACE1 was readily detectable as an 70 kDa species in
protein extracts from hippocampus of nontransgenic mice (Fig.
5B, lane 1), whereas the immunoreactive band was absent in the
protein extract from the hippocampus of BACE1-deficient mice
(Fig. 5B, lane 4). In contrast, we were unable to detect BACE1 in
detergent homogenates from sciatic nerve extracts from mice
(Fig. 5B, compare lanes 2, 3, 5, 6). An immunoreactive band of
the same size as BACE1 was detected in sciatic nerve extract
of BACE1 KOmice, suggesting a nonspecific binding interaction
of this polypeptide with the antibody in the sciatic nerve (Fig. 5B,
lanes 5, 6). Moreover, there was no increase in levels of immuno-
reactive bands in the proximal segment compared with the distal
segment of ligated nerves (Fig. 5B, lanes 2, 3). Notably, we ob-
served elevated levels of mature, fully glycosylated APP in the
hippocampus from BACE1-deficient mice (Fig. 5B, lane 4), as
would be expected if BACE1 is inactivated.
Together, the absence of detectable BACE1 and A in periph-
eral nerves is inconsistent with amodel that proposes cotransport
Figure 4. PS1 is not cotransported with APP in the same vesicular compartment by fast
axonal transport. A, Top, Schematic diagram of sciatic nerve double ligation and nerve seg-
ments examined for protein expression. Bottom, Expression level of APP and PS1 in nerve
segments at varying distances from the site of ligation in sciatic nerve of nontransgenic mice.
APP expression level increases toward the site of ligation, whereas it decreases away from the
distal ligature (CT15 panel, lanes 1–5). In contrast, PS1 expression level is comparable in intact
sciatic nerve and nerve segments at varying distances from the site of ligation (PS1-NTF panel,
lanes 1–7). B, APP and PS1 immunoreactivity in cryostat sections of the proximal and distal
ends of ligated sciatic nerve.A,B, APP is detectedusing CT15 antibodies. Note the accumulation
of APP proximal to the ligature (A), whereas weak immunoreactivity is observed at the distal
stump (B). C,D, PS1 immunoreactivity as detected by affinity-purifiedPS1-NTF antibodies; C,
proximal stump; D, distal stump. Note that neither accumulation at the proximal stump nor
reduced immunoreactivity at thedistal stump canbedetected.E, Specificity of immunostaining
for PS1 was confirmed usingPS1-NTF antibodies preincubated with GST-PS1-NTF (seeMate-
rials andMethods). F, Immunostaining ofmouse sciatic nerve cryostat sections using secondary
antibodies only (fluorescein-conjugated goat anti-rabbit). Scale bar, 200m.
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of the processing machinery that generates A peptides in com-
partments within the axons. Thus, we conclude that in peripheral
nerves APP is not coresident with components of the processing
machinery within anterogradely transported membrane vesicles
in peripheral axons. Furthermore, the absence of any detectable
effects on the transport of known kinesin-1 cargos or of kinesin-1
itself in peripheral nerve in the absence of detectable APP is in-
consistent with a role for APP as a receptor for kinesin-1.
Discussion
The unequivocal demonstrations that APP moves in fast antero-
grade transport inmammalian axons (Koo et al., 1990; Buxbaum
et al., 1998) and the compelling demonstration that APP is pro-
teolytically processed at nerve terminals have spurred efforts to
examine the role played by APP in anterograde movement of
membranous cargos and the molecular apparatus involved in
APP processing in neurons. It has been reported that the cyto-
plasmic domain of APP binds with high affinity to the TR do-
mains of KLC and that an APP–kinesin-1 complex is associated
in vivo (Kamal et al., 2000). These findings, together with the
observation that APP transport is impaired in mice with func-
tionally ablated KLC1 alleles, led to the hypothesis that APP
serves as a kinesin-1 cargo receptor (Kamal et al., 2000). In addi-
tion, it was suggested that PS1, a component of the -secretase
machinery responsible for intramembranous processing of APP,
is cotransported in the same vesicle cargo with APP (Kamal et al.,
2001). Moreover, these studies suggested
that BACE1 is rapidly transported antero-
gradely in APP-containing vesicles within
nerves and thatA40 andA42 peptides are
generated during transport (Kamal et al.,
2001). These findings, if replicated, would
not only be of value in identifying an im-
portant functional role for APP, but also
suggest a paradigm shift in our under-
standing of the pathogenesis of AD. In this
report, we performed a series of experi-
ments to test the hypothesis that APP
serves as a kinesin-1 cargo receptor and
that the molecular components involved
in APP processing are cotransported in the
sciatic nerves of wild-type and APPswe
mice. Our findings are summarized below.
In contrast to the studies of Kamal et al.
(2000), we were not able to demonstrate a
direct interaction between APP and either
KHC or KLC in vitro and in vivo. Because
APP was reported to bind directly to the
TR domains in KLCs with stoichiometry
of two APP/KLC, we first examined possi-
ble direct interactions between these mol-
ecules using in vitro binding assays with
recombinant KLC and APP fusion pro-
teins (Kamal et al., 2000). Although we
noted binding of the APP-ICD fusion pro-
tein to the KLC1 fusion protein, this may
not reflect a physiologically relevant inter-
action. A wide variety of structurally unre-
lated proteins have been reported to inter-
act with KLC through these domains,
including Drosophila kinesin-1 associated
protein YETI (Wisniewski et al., 2003),
JIP1 and JIP2 (Matsuda et al., 2001; Ver-
hey et al., 2001), Sunday Driver (Bowman
et al., 2000), surface proteins in vaccinia virus (Ward and Moss,
2004), and the chaperone hsc70 (Tsai et al., 2000), as well as
various unpublished interactions. The evidence thus suggests
that TRs may be involved in protein–protein interactions, but
TRs are poor candidates for determining cargo specificity. TR
domain sequences are homologous in both KLC1 and KLC2 and
highly conserved at the amino acid level (Tsai et al., 2000). None-
theless, KLC1 and KLC2 appear to be associated with different
subsets of membrane-bound organelles (Leopold et al., 1992; El-
luru et al., 1995; Stenoien and Brady, 1997; Rahman et al., 1999).
Hydrophobic stretches in TRswould tend to drive relatively non-
specific binding with other proteins containing suitable hydro-
phobic patches. This feature is a potential source of artifact for in
vitro binding assays, making confirmation of putative interac-
tions with in vivo assays critical. In our study, a series of in vivo
assays with endogenous kinesin-1 and APP indicate that there is
not a direct interaction between these two proteins. APP and
kinesin-1 did not cofractionate under conditions in which
kinesin-1 is retained on membrane fractions. In particular, there
was no match between the distribution of KLC1 and APP, the
proposed interacting partners (Kamal et al., 2000, 2001). Simi-
larly, APP and kinesin-1 did not coimmunoprecipitate under
nondenaturing conditions from lysates of mouse brain with any
of a wide range of specific antibodies to different epitopes on
KLC, KHC, and APP. In these experiments, KHC and KLC re-
Figure 5. Expression of BACE1 and A is undetectable in mouse sciatic nerve. A, Western blot analysis of A expression in
protein extracts of stably transfected APPsweN2a cells (lane 1), APPsweN2a cells and sciatic nerve extract (lane 2), cortex (ctx) of
transgenic mice harboring APPswe (lane 3), and ligated sciatic nerve of transgenic mice harboring APPswe (lanes 4–6). I, Intact
contralateral nerve; P, segment proximal to the ligature; D, segment distal to the ligature. Accumulation of C-terminal fragments
is shown, but no A could be detected at the proximal stump of sciatic nerve of the FAD-linked APPswe variant (lanes 4–6).
C-terminal fragments, as well as low levels of A, could be detected in protein extract from the cortex of these mice using an
amount of protein equivalent to that of the sciatic nerve extracts (lane 3; note “A long exposure”). A could be detected in N2a
cells stably transfectedwith APPswe. Addition of nerve extract to N2a cells yielded the same level of A as N2a alone (lanes 1 and
2, respectively). B, No specific band corresponding to BACE1 could be detected in protein extracts of ligated mouse sciatic nerve
after crush injury. SN-P, Sciatic nerve segment proximal to the crush site; SN-D, sciatic nerve segment distal to the crush site. A
band similar to the one observed in nontransgenic mice proximal and distal to the crush injury (BACE1 panel, lanes 2 and 3,
respectively) was observed in protein extract of BACE1 KO sciatic nerve (BACE1 panel, lanes 5 and 6, respectively). To confirm our
ability todetectBACE1,weexaminedBACE1expression in thehippocampusof thesemice. BACE1wasdetectable in thehippocam-
pus (Hipp) of nontransgenic mice (BACE1 panel, lane 1) but not in the hippocampus of BACE1 KOmice (BACE1 panel, lane 4). APP
accumulated at the proximal segment of the crushed injury in the sciatic nerve of both the nontransgenicmice (APP panel, lane 2)
and the BACE1 KOmice (APP panel, lane 5), confirming the blockade of fast anterograde axonal transport after the crush injury. As
expected, increased expression of APPwas observed in the hippocampus of BACE1 knock-outmice comparedwith nontransgenic
mice (APP panel, compare lanes 4 and 1, respectively).
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mained associated, indicating that high-affinity protein com-
plexes were preserved.
Although Kamal et al. (2000, 2001) suggested that APP is re-
quired for kinesin-1-mediated axonal transport, we did not ob-
serve differences in the steady-state levels of KHC and KLC in
sciatic nerves of APP-deficient mice compared with wild-type
mice, nor were there differences in levels of kinesin-1 that accu-
mulated in the proximal segment of ligated sciatic nerves from
APP-deficient and wild-type animals. Consistent with this study,
we showed that axonal transport of Trk also occurs in an APP-
independent manner. The lack of effects of APP deficiency on
axonal transport of kinesin-1 and Trk, and the lack of a direct
association between kinesin-1 and APP in brain, leads us to con-
clude that APP is an unlikely candidate for a kinesin-1 cargo
receptor, at least in peripheral nerves. In support of these find-
ings, we (E. B. Lee andV.M.-Y. Lee) have shown that overexpres-
sion of BACE1 leads to a reduction in levels of axonally trans-
ported APP in the sciatic nerve, but without impairment in the
transport of synaptophysin and kinesin-1 (Lee et al., 2005).
Clearly, APP is present in one ormore of themembrane cargo
vesicles moved by kinesin-1, but it is not required for the trans-
port of those vesicles and does not attach directly to the kinesin-1
motor. This observation is consistent with the fact that APP KO
mice are viable and phenotypically near normal (Zheng et al.,
1995), whereas knock-outs of specific KHC (Tanaka et al., 1998;
Kanai et al., 2000) or KLC1 (Rahman et al., 1999) genes are em-
bryonic lethal, with neurological defects; however, it is still con-
ceivable that APP and kinesin-1 could interact indirectly with a
connectionmediated by a linker protein. For example, amember
of the JNK-signaling scaffold protein family, JIP1b, was reported
to enhance the “interaction” of APP and kinesin-1 in vitro; how-
ever, these data are based only on in vitro analyses. Considering
the tendency of KLC to bind nonspecifically to hydrophobic
stretches, these data need clarification and further support by in
vivo analysis.
Although Kamal et al. (2001) suggested that PS1 and APP are
cotransported in rapid anterograde transport in sciatic nerve, our
results do not support this hypothesis. For example, the steady-
state levels of PS1 in unligated and ligated sciatic nerves of mice
with functionally ablated APP genes are not different from those
measured in nerves from wild-type mice, thus arguing against
cotransport of APP and PS1 in the same vesicle component. Al-
though it is conceivable that only small amounts of PS1 exit the
cell body at a given time and any signal might be masked by the
abundant levels of PS1 in the proximal segment that is contrib-
uted by cells intrinsic to the nerve itself, we consider this unlikely,
because our immunohistochemical studies did not reveal accu-
mulation of PS1 immediately proximal to the ligature during the
intervals examined.
Additionally, we were not able to detect BACE1 or A in
sciatic nerves, nor were we able to detect accumulation of these
polypeptides in the proximal segment of ligated nerves. Thus, our
results do not support the hypothesis that components of the
APP proteolytic processing machinery that are responsible for
generating A and A itself are cotransported with APP in the
fast transport component in peripheral nerves.
Many hypotheses have been generated to explain the func-
tions or pathological roles of APP, PS1, BACE1, and other com-
ponents of the complex that produce A. For many years, the
complexity of the disease and the absence of good animal models
for ADmade it difficult to evaluate the validity of these proposals,
but currently available models and methodologies now may be
used to test these hypotheses. The idea that all of the components
for producing A were localized in a single compartment had an
attractive simplicity, but it was not consistent with what is known
about the biology of A and amyloid. The relative levels of the
different components, their subcellular localization, and their
varied biological roles are all inconsistent with a single compart-
ment. Our test of the one-compartment model (Kamal et al.,
2001) indicated that APP, PS1, and BACE1 exist primarily in
different compartments in peripheral nerves. It may be that
secretases are transported in these axons, but the levels (in con-
trast to APP) are so low that they are not detectable. More signif-
icantly, the levels of the secretases do not appear sufficient to
generate A that could deposit at sensory terminals or neuro-
muscular junctions. The situation may be different in CNS neu-
rons, including basal forebrain cholinergic and entorhinal cortex
neurons. In these cells, levels of APP and critical secretases appear
to be sufficient to generate A levels that lead to the formation of
oligomeric species at synapses, leading to synaptic dysfunction
and A aggregation. In neurons, the various components of the
APP processing complex must be specifically assembled at some
point and transported before encountering membrane-tethered
APP-CTFs to generate A. Recognition of this requirement is an
important step forward for our understanding of pathogenesis in
Alzheimer’s disease and possibly for the development of new
therapeutics for targeting the formation and potential toxic ef-
fects of A peptides.
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